Olanzapine enabled rechallenge after lorlatinib‐induced psychosis: A case report

Olanzapine enabled rechallenge after lorlatinib‐induced psychosis: A case report

Abstract Background Lorlatinib is a third‐generation tyrosine kinase inhibitor for anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer (NSCLC). While it has a high intracranial lesion control rate, it can also cause central nervous system complications, including psychotic symptoms....

Full description

Saved in:
Bibliographic Details
Main Authors: Akiyoshi Yokode, Masaki Fujiwara, Yuko Nakamura, Kadoaki Ohashi, Shinji Sakamoto, Manabu Takaki
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:PCN Reports
Subjects:
psycho‐oncology
lorlatinib
lung cancer
medication‐induced psychosis
Online Access:https://doi.org/10.1002/pcn5.70091
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items